巴曲酶治疗急性脑梗死的临床疗效

目的:观察巴曲酶治疗急性脑梗死的临床疗效。方法:将94例急性脑梗死患者随机分为治疗组和常规组。治疗组46例,首先应用巴曲酶分别10,5,SBU,qod,iv gtt,共3次,然后予以尼莫地平治疗;常规组48例,仅用尼莫地平治疗。结果:治疗组基本治愈20例(43％),显著进步20例(43％),总有效率94％;常规组基本治愈5例(10％),显著进步15例(31％),总有效率80%,治疗组疗效明显优于常规组(P<0.05)。结论:巴曲酶治疗急性脑梗死的疗效肯定,且明显减低了病残率。

Clinical effect of batroxobin in treatment of patients with acute cerebral infarction

AIM: To observe the clinical effect of batroxobin in treatment of patients with acute cerebral infarction. METHODS: Ninety-four patients with acute cerebral infarction were randomly divided into treatment group (46 patients) and control group (48 patients) . The treatment group was given batroxobin 10, 5, 5BU after an interval of one day with intravenous drip, followed by nimodipine; while the control group was treated with nimodipine alone. RESULTS : Basic heal rate of the batroxobin treatment group was 43% , remarkable improvement rate was 43% , the efficacy rate was 94% and in control group the basic heal rate was 10% , remarkable improvement rate was 31 % , the effective rate was 80% both showed a significant difference statistically ( P < 0.05). CONCLUSION: Batroxobin is definitely effective and evidently decrease disability ratio in treating acute cerebral infarction.